Silicosis is a progressive occupational lung disease requiring structured management directed at relieving respiratory symptoms, halting functional decline, and achieving measurable improvement in lung status. A first-line protocol addresses these goals through a defined set of interventions.
Management combines broncho-pulmonary procedural intervention — applicable at an early disease category — with a pharmacological agent that has received regulatory approval specifically for silicosis, together with additional supportive strategies matched to disease severity. The full selection criteria, sequencing, and individualized adjustments are detailed in the complete protocol.
DOI: 10.1155/2022/3769134
Large volume whole-lung lavage is often used at an early category of silicosis to improve chest tightness, chest pain, shortness of breath, and other related symptoms.
Tetrandrine, which has been approved to treat silicosis in China, can inhibit lung inflammation and lung fibrosis to improve pulmonary function.
Clinical trials have shown that patients' lung function, quality of life, and exercise ability have significantly improved after treatment with traditional Chinese medicines.
Successful exercise progression maximizes improvements and sustained treatment effects favor those with milder interstitial lung diseases.
View source ↗